---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016286"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:15:24.454772+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Imunon Q1 net loss narrows to $5.6M; cash runway into 2025; PLACCINE IND planned Q4 2023

## Summary
- Net loss of $5.6M ($0.68/share) vs $10.5M ($1.82/share) in Q1 2022; operating expenses down 5% to $5.7M.
- Cash and equivalents $37.3M at March 31, 2023; expects funding operations into 2025, plus $1.9M in NJ NOL sales.
- Phase 1/2 trial of IMNN-001 + Avastin in advanced ovarian cancer opened for enrollment at MD Anderson and others.
- Pre-IND consultation filed with FDA for PLACCINE COVID-19 booster; IND expected Q4 2023.
- Collaborated with Wistar Institute to develop PLACCINE vaccines for infectious diseases.

## SEC filing metadata
- accession: 0001493152-23-016286
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/0001493152-23-016286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016286
- JSON: https://secwatch.observer/filing/0001493152-23-016286.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016286.txt

## Key facts
- Earnings Releases
  Imunon, Inc. reported financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: reported results
  source text: IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/0001493152-23-016286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.